Cargando…

Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment

BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in inhabitants from low-income countries and in visitors to these countries. The impact of the human intestinal microbiota on the initiation and progression of ETEC diarrhea is not yet well understood. RESULTS: We used...

Descripción completa

Detalles Bibliográficos
Autores principales: Pop, Mihai, Paulson, Joseph N., Chakraborty, Subhra, Astrovskaya, Irina, Lindsay, Brianna R., Li, Shan, Bravo, Héctor Corrada, Harro, Clayton, Parkhill, Julian, Walker, Alan W., Walker, Richard I., Sack, David A., Stine, O. Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898365/
https://www.ncbi.nlm.nih.gov/pubmed/27277524
http://dx.doi.org/10.1186/s12864-016-2777-0
_version_ 1782436341288534016
author Pop, Mihai
Paulson, Joseph N.
Chakraborty, Subhra
Astrovskaya, Irina
Lindsay, Brianna R.
Li, Shan
Bravo, Héctor Corrada
Harro, Clayton
Parkhill, Julian
Walker, Alan W.
Walker, Richard I.
Sack, David A.
Stine, O. Colin
author_facet Pop, Mihai
Paulson, Joseph N.
Chakraborty, Subhra
Astrovskaya, Irina
Lindsay, Brianna R.
Li, Shan
Bravo, Héctor Corrada
Harro, Clayton
Parkhill, Julian
Walker, Alan W.
Walker, Richard I.
Sack, David A.
Stine, O. Colin
author_sort Pop, Mihai
collection PubMed
description BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in inhabitants from low-income countries and in visitors to these countries. The impact of the human intestinal microbiota on the initiation and progression of ETEC diarrhea is not yet well understood. RESULTS: We used 16S rRNA (ribosomal RNA) gene sequencing to study changes in the fecal microbiota of 12 volunteers during a human challenge study with ETEC (H10407) and subsequent treatment with ciprofloxacin. Five subjects developed severe diarrhea and seven experienced few or no symptoms. Diarrheal symptoms were associated with high concentrations of fecal E. coli as measured by quantitative culture, quantitative PCR, and normalized number of 16S rRNA gene sequences. Large changes in other members of the microbiota varied greatly from individual to individual, whether or not diarrhea occurred. Nonetheless the variation within an individual was small compared to variation between individuals. Ciprofloxacin treatment reorganized microbiota populations; however, the original structure was largely restored at one and three month follow-up visits. CONCLUSION: Symptomatic ETEC infections, but not asymptomatic infections, were associated with high fecal concentrations of E. coli. Both infection and ciprofloxacin treatment caused variable changes in other bacteria that generally reverted to baseline levels after three months. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-016-2777-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4898365
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48983652016-06-09 Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment Pop, Mihai Paulson, Joseph N. Chakraborty, Subhra Astrovskaya, Irina Lindsay, Brianna R. Li, Shan Bravo, Héctor Corrada Harro, Clayton Parkhill, Julian Walker, Alan W. Walker, Richard I. Sack, David A. Stine, O. Colin BMC Genomics Research Article BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in inhabitants from low-income countries and in visitors to these countries. The impact of the human intestinal microbiota on the initiation and progression of ETEC diarrhea is not yet well understood. RESULTS: We used 16S rRNA (ribosomal RNA) gene sequencing to study changes in the fecal microbiota of 12 volunteers during a human challenge study with ETEC (H10407) and subsequent treatment with ciprofloxacin. Five subjects developed severe diarrhea and seven experienced few or no symptoms. Diarrheal symptoms were associated with high concentrations of fecal E. coli as measured by quantitative culture, quantitative PCR, and normalized number of 16S rRNA gene sequences. Large changes in other members of the microbiota varied greatly from individual to individual, whether or not diarrhea occurred. Nonetheless the variation within an individual was small compared to variation between individuals. Ciprofloxacin treatment reorganized microbiota populations; however, the original structure was largely restored at one and three month follow-up visits. CONCLUSION: Symptomatic ETEC infections, but not asymptomatic infections, were associated with high fecal concentrations of E. coli. Both infection and ciprofloxacin treatment caused variable changes in other bacteria that generally reverted to baseline levels after three months. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-016-2777-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-08 /pmc/articles/PMC4898365/ /pubmed/27277524 http://dx.doi.org/10.1186/s12864-016-2777-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pop, Mihai
Paulson, Joseph N.
Chakraborty, Subhra
Astrovskaya, Irina
Lindsay, Brianna R.
Li, Shan
Bravo, Héctor Corrada
Harro, Clayton
Parkhill, Julian
Walker, Alan W.
Walker, Richard I.
Sack, David A.
Stine, O. Colin
Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment
title Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment
title_full Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment
title_fullStr Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment
title_full_unstemmed Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment
title_short Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment
title_sort individual-specific changes in the human gut microbiota after challenge with enterotoxigenic escherichia coli and subsequent ciprofloxacin treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898365/
https://www.ncbi.nlm.nih.gov/pubmed/27277524
http://dx.doi.org/10.1186/s12864-016-2777-0
work_keys_str_mv AT popmihai individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT paulsonjosephn individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT chakrabortysubhra individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT astrovskayairina individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT lindsaybriannar individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT lishan individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT bravohectorcorrada individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT harroclayton individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT parkhilljulian individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT walkeralanw individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT walkerrichardi individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT sackdavida individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment
AT stineocolin individualspecificchangesinthehumangutmicrobiotaafterchallengewithenterotoxigenicescherichiacoliandsubsequentciprofloxacintreatment